/PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of.
Bausch Health Companies Inc. today announced that Tom Vadaketh will join the Company as Chief Financial Officer for its Bausch Pharma business effective Jan. 3, 2022 . Sam Eldessouky current CFO of the Company, will become CFO of Bausch + Lomb contingent and effective upon the closing of the initial public offering of Bausch + Lomb, and at that time, Mr. Vadaketh will assume the role of CFO of Bausch Pharma. Mr. .
/PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2021 financial results on Tuesday, Nov. 2, 2021..
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 in Dry Eye Disease Associated with Meibomian Gland Dysfunction investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.